Modality
Cell Therapy
MOA
EZH2i
Target
LAG-3
Pathway
Wnt
Pancreatic Ca
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
~Jan 2024
→ ~Apr 2025
Phase 2
Jul 2025
→ Sep 2025
Phase 2Current
NCT06389167
1,249 pts·Pancreatic Ca
2025-07→2025-09·Not yet recruiting
1,249 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-067mo agoPh2 Data· Pancreatic Ca
Trial Timeline
Q3
P2
Not yet…
Catalysts
Ph2 Data
2025-09-06 · 7mo ago
Pancreatic Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06389167 | Phase 2 | Pancreatic Ca | Not yet recr... | 1249 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |